Skip to main content

Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues

Edited by:

Anna Dimberg, PhD, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Sweden
Paola Nisticò, MD, IRCCS-Regina Elena National Cancer Institute, Italy 
Nicla Porciello, PhD, IRCCS-Regina Elena National Cancer Institute, Italy 
Alice Castelli, PhD, Managing Editor, Journal of Experimental & Clinical Cancer Research, IRCCS-Regina Elena National Cancer Institute, Italy

Submission Status: Open   |   Submission Deadline: 30 June 2025 


Journal of Experimental & Clinical Cancer Research is calling for submissions to our Collection on “Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues”. In this Collection, we aim to offer a comprehensive overview of the current landscape of the Tumor Immune Microenvironment (TIME) properties, considering cellular and non-cellular components, emphasizing innovative technologic tools to clinically translate recent research breakthroughs (1).

About the Collection

Journal of Experimental & Clinical Cancer Research is calling for submissions to our Collection on “Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues”. In this Collection, we aim to offer a comprehensive overview of the current landscape of the Tumor Immune Microenvironment (TIME) properties, considering cellular and non-cellular components, emphasizing innovative technologic tools to clinically translate recent research breakthroughs (1). Cancer-intrinsic factors such as genetic alterations, a broad range of cellular TIME components including cancer-associated fibroblasts, endothelial cells, and immune cells, along with extracellular matrix and soluble factors like cytokines, interact with each other to either suppress or favor anti-tumor immunity (2-7). Unveiling this reciprocal dialogue, the dynamics, and the spatial positioning of TIME components is fundamental to improving patient clinical outcomes and identifying the molecular mechanisms underlying TIME-mediated immunomodulation and utilize TIME landscape for clinical applications. The integration of high-resolution technologies and computational developments is significantly accelerating the addressing of these fundamental issues. This may open up novel translational and clinical opportunities for the development of more effective therapeutic combinations with the potential to significantly improve and broaden the response to therapy in solid tumors. 

References:

1. Toninelli M, Rossetti G, Pagani M. Charting the tumor microenvironment with spatial profiling technologies. Trends Cancer. 2023 Dec;9(12):1085-1096
2. Di Modugno F, Di Carlo A, Spada S, Palermo B, D'Ambrosio L, D'Andrea D, Morello G, Belmonte B, Sperduti I, Balzano V, Gallo E, Melchionna R, Panetta M, Campo G, De Nicola F, Goeman F, Antoniani B, Carpano S, Frigè G, Warren S, Gallina F, Lambrechts D, Xiong J, Vincent BG, Wheeler N, Bortone DS, Cappuzzo F, Facciolo F, Tripodo C, Visca P, Nisticò P. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer. EBioMedicine. 2024 Mar;101:105003
3. Ramachandran M, Vaccaro A, van de Walle T, Georganaki M, Lugano R, Vemuri K, Kourougkiaouri D, Vazaios K, Hedlund M, Tsaridou G, Uhrbom L, Pietilä I, Martikainen M, van Hooren L, Olsson Bontell T, Jakola AS, Yu D, Westermark B, Essand M, Dimberg A. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell. 2023 Jun 12;41(6):1134-1151
4. Enfield KSS, Colliver E, Lee C, Magness A, Moore DA, Sivakumar M, Grigoriadis K, Pich O, Karasaki T, Hobson PS, Levi D, Veeriah S, Puttick C, Nye EL, Green M, Dijkstra KK, Shimato M, Akarca AU, Marafioti T, Salgado R, Hackshaw A; TRACERx consortium; Jamal-Hanjani M, van Maldegem F, McGranahan N, Glass B, Pulaski H, Walk E, Reading JL, Quezada SA, Hiley CT, Downward J, Sahai E, Swanton C, Angelova M. Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer. Cancer Discov. 2024 Jun 3;14(6):1018-1047
5. Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J, Sun CM, Laurent-Puig P, Vano YA, Elaïdi R, Méjean A, Sanchez-Salas R, Barret E, Cathelineau X, Oudard S, Reynaud CA, de Reyniès A, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022 Mar 8;55(3):527-541
6. Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 2023 Mar;23(3):173-188
7. Croizer H, Mhaidly R, Kieffer Y, Gentric G, Djerroudi L, Leclere R, Pelon F, Robley C, Bohec M, Meng A, Meseure D, Romano E, Baulande S, Peltier A, Vincent-Salomon A, Mechta-Grigoriou F. Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer. Nat Commun. 2024 Apr 1;15(1):2806

Keywords: Tumor Immune Microenvironment, Immune cells, Tertiary Lymphoid Structures, Cancer Associated Fibroblasts, Endothelial Cells, Spatial Transcriptomics, Cytokines, Solid Tumors 

Image credit: © Nicla Porciello

  1. Melanoma progression is based on a close interaction between cancer cells and immune cells in the tumor microenvironment (TME). Thus, a better understanding of the mechanisms controlling TME dynamics and compo...

    Authors: Alessandro Giammona, Chiara De Vellis, Enrica Crivaro, Luisa Maresca, Roberta Amoriello, Federica Ricci, Giulia Anichini, Silvia Pietrobono, David R. Pease, Martin E. Fernandez-Zapico, Clara Ballerini and Barbara Stecca
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:214
  2. Pancreatic cancer (PC) is a clinically challenging tumor to combat due to its advanced stage at diagnosis as well as its resistance to currently available therapies. The absence of early symptoms and known det...

    Authors: Carla Mottini, Francesca Romana Auciello, Isabella Manni, Christian Pilarsky, Damiano Caputo, Giulio Caracciolo, Alessandro Rossetta, Elena Di Gennaro, Alfredo Budillon, Giovanni Blandino, Maria Serena Roca and Giulia Piaggio
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:198
  3. Pyroptosis is a cell death process characterized by cell swelling until membrane rupture and release of intracellular contents. As an effective tumor treatment strategy, inducing tumor cell pyroptosis has rece...

    Authors: Mengyuan Hu, Fengying Deng, Xinlei Song, Hongkun Zhao and Fei Yan
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:190

Submission Guidelines

Back to top

This Collection welcomes submission of Research articles and Reviews. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, Editorial Manager. Please select the appropriate Collection title “Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues" from the dropdown menu. Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.